Drug Acquisition Programs Can Improve Access to Treatment


City of Hope has successfully targeted patients facing barriers, according to the authors, who published a summary highlighting the study ahead of the 2023 ASCO Annual Meeting in Chicago, Illinois. He said he created a Drug Acquisition Program (MAP) to help people get personalized treatment and immunotherapy.

Credit: Prostock-studio-stock.adobe.com.

Under the supervision of one certified oncology nurse, the MAP program has demonstrated a 99% success rate in helping patients receive appropriate treatment. This has been made possible through appeals to payers and patient assistance programs. In addition, her 34% of patients experienced direct clinical benefit, defined as a treatment duration of ≥4 months, from interventions established through the MAP program.

“[MAP] “We were able to provide patients with targeted therapies that they otherwise would not have received, while enhancing our center’s ability to provide innovative options for patients who have exhausted standard of care (SoC) options,” the study authors said. states in the abstract.

Genomic testing is becoming increasingly popular in identifying clinical trial candidates to study new innovations in precision medicine, but patients are not always eligible for clinical trials. Clinical, financial, and administrative challenges may prevent patients from accessing these targeted therapies, which could provide significant benefit, and there are known barriers, including:

  • clinical trials are no longer available,
  • Out-of-pocket costs are too high for patients with government-provided insurance,
  • Treatment is excluded from the insurance policy.
  • Insurance plans deny coverage for off-label or on-label indications.

Researchers conducted a retrospective clinical study to understand how the program improves access to targeted therapies and improves clinical outcomes associated with these therapies. The team examined data on patients who received targeted therapy, who were indicated for her SoC with another tumor type, or who were denied access because of their indication.

The MAP program received 1,041 referrals from October 2015 to December 2021, with 769 patients starting treatment. Of the treated patients, 66% received ≤3 months of therapy, 16% received 4-6 months of therapy, 8% received 7-10 months of therapy, and 10% received 11 Received more than 1 month of targeted therapy. In total, his 34% of patients experienced clinical response at least in her 4 months of treatment.

Of the patients who started treatment through the MAP program, 44% progressed and required further treatment, while 68% received additional treatment and were able to continue treatment at the cancer center.

reference

Doctor V, Schink J, Moran A, Gandra N, Markman M. Drug acquisition programs – successful access to innovative treatment options. Venue: American Society of Clinical Oncology Annual Meeting. From June 2nd to June 6th, 2023. Chicago, Illinois.

https://conferences.asco.org/am/registration?cmpid=cc_ascoorg_am_genreg-finalpush_psrh_google_brand__intl_051623_060623___aware_text_genreg-finalpush-brand&gad=1&gclid=Cj0KCQjwyLGjBhDKARIsAFRNgW8wdWt4oC2-cqM7yVmpm 5btwZHi0yYPCzFFNzhSqWrp-WI0HIGojW4aAj5BEALw_wcB



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *